Center For Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Center For Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-677	Closed	-$307K	–	154
2025 Q4	$307K	Buy	+677	New	+$292K	0.16%	112
2024 Q3	–	Sell	-1,714	Closed	-$803K	–	130
2024 Q2	$803K	Sell	1,714 -10	-0.6%	-$4.34K	0.53%	45
2024 Q1	$721K	Hold	1,724	–	–	0.59%	39
2023 Q4	$701K	Sell	1,724 -1,196	-41%	-$442K	0.64%	38
2023 Q3	$1.02M	Sell	2,920 -86	-3%	-$30.1K	1.01%	25
2023 Q2	$1.06M	Buy	3,006 +1,979	+193%	+$667K	1%	26
2023 Q1	$324K	Buy	+1,027	New	+$308K	0.32%	79

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Center For Asset Management's VRTX Position: Q1 2026 in Review

Center For Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 677 shares — an estimated $307K sold.

Center For Asset Management first reported a position in VRTX in Q1 2023 and held it in 7 quarters. The position peaked at $1.06M in Q2 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Center For Asset Management reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Center For Asset Management sold 677 Vertex Pharmaceuticals shares in Q1 2026, an estimated $307K.
Center For Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2023 and held it in 7 quarters.
Center For Asset Management's Vertex Pharmaceuticals position peaked at $1.06M in Q2 2023.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Center For Asset Management's 13F filing for Q1 2026, filed 16 Apr 2026.